Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation

Reduction of severe acute graft-versus-host disease using a combination of pre transplant... Bone Marrow Transplantation (2018) 53:361–365 https://doi.org/10.1038/s41409-017-0053-9 CORRESPONDENCE Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation 1 2 1 1 1 ● ● ● ● ● Uday Deotare Eshetu G. Atenafu David Loach Fotios V. Michelis Dennis (Dong-Hwan) Kim 1 1 1 1 ● ● ● Santhosh Thyagu Jeffrey H. Lipton Hans A. Messner Auro Viswabandya Received: 2 May 2017 / Revised: 6 October 2017 / Accepted: 23 October 2017 / Published online: 21 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Use of Post-transplant Cyclophosphamide (PTCy) has associated with severe forms of GVHD. Here we present recently been introduced specifically in the haplo-identical the preliminary outcome in our unrelated patients using transplant setting with promising results [1]. This inter- this regimen. vention has also shown a significant reduction of acute This is a retrospective study of the patient cohort treated graft versus host disease (aGVHD) and a trend towards from 1 October 2015 until 31 March 2016 in a single center. improving chronic graft versus host disease (cGVHD) [2]. This study was approved by the institutional Research The efficacy of PTCy has http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bone Marrow Transplantation Springer Journals

Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation

Loading next page...
 
/lp/springer_journal/reduction-of-severe-acute-graft-versus-host-disease-using-a-VF6JGu4zjC
Publisher
Nature Publishing Group UK
Copyright
Copyright © 2017 by The Author(s) 2017, under exclusive licence to Macmillan Publishers Limited, part of Springer Nature
Subject
Medicine & Public Health; Medicine/Public Health, general; Internal Medicine; Cell Biology; Public Health; Hematology; Stem Cells
ISSN
0268-3369
eISSN
1476-5365
D.O.I.
10.1038/s41409-017-0053-9
Publisher site
See Article on Publisher Site

Abstract

Bone Marrow Transplantation (2018) 53:361–365 https://doi.org/10.1038/s41409-017-0053-9 CORRESPONDENCE Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation 1 2 1 1 1 ● ● ● ● ● Uday Deotare Eshetu G. Atenafu David Loach Fotios V. Michelis Dennis (Dong-Hwan) Kim 1 1 1 1 ● ● ● Santhosh Thyagu Jeffrey H. Lipton Hans A. Messner Auro Viswabandya Received: 2 May 2017 / Revised: 6 October 2017 / Accepted: 23 October 2017 / Published online: 21 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Use of Post-transplant Cyclophosphamide (PTCy) has associated with severe forms of GVHD. Here we present recently been introduced specifically in the haplo-identical the preliminary outcome in our unrelated patients using transplant setting with promising results [1]. This inter- this regimen. vention has also shown a significant reduction of acute This is a retrospective study of the patient cohort treated graft versus host disease (aGVHD) and a trend towards from 1 October 2015 until 31 March 2016 in a single center. improving chronic graft versus host disease (cGVHD) [2]. This study was approved by the institutional Research The efficacy of PTCy has

Journal

Bone Marrow TransplantationSpringer Journals

Published: Dec 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial